| Generic Name | Rosuvastatin/Ezetimibe |
| Strength | Rosuvastatin/Ezetimibe 20mg/10mg |
| Indication/Usage | Primary Hypercholesterolaemia/ Homozygous Familial Hypercholesterolaemia (HoFH) Rosuvastatin / Ezetimibe (Zenon) is indicated as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia in adult patients: • who are not appropriately controlled with statin alone, • who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products. Prevention of Cardiovascular Events Rosuvastatin / Ezetimibe (Zenon) is indicated as substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently, at the same dose level as in the fixed dose combination, but as separate products to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS). |
| Dosage and Administration | Rosuvastatin / Ezetimibe (Zenon) is not suitable for initial therapy. When Rosuvastatin / Ezetimibe (Zenon) is indicated for patients not controlled by statin alone, the dose of Rosuvastatin / Ezetimibe (Zenon) should be individualized according to the target lipid levels and the patient's response. When Rosuvastatin / Ezetimibe (Zenon) is indicated for patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate product, treatment initiation or dose adjustment if necessary should only be done with the monocomponents and after setting the appropriate doses the switch to the fixed dose combination of the appropriate strength is possible. Patient should use the strength corresponding to their previous treatment. The recommended dose is one Rosuvastatin / Ezetimibe (Zenon) tablet daily. |
| Warning and Precautions | Skeletal muscle effects Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in rosuvastatin-treated patients with all doses and in particular with doses >20 mg. As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with rosuvastatin in post-marketing use is higher at the 40 mg dose. In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported. However, rhabdomyolysis has been reported very rarely with ezetimibe monotherapy and very rarely with the addition of ezetimibe to other agents known to be associated with increased risk of rhabdomyolysis. If myopathy is suspected based on muscle symptoms or is confirmed by a creatine phosphokinase (CPK) level, Rosuvastatin / Ezetimibe (Zenon) and any of these other agents that the patient is taking concomitantly should be immediately discontinued. All patients starting therapy with Rosuvastatin / Ezetimibe (Zenon) should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness. Creatine kinase measurement Creatine kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (>5xULN) a confirmatory test should be carried out within 5-7 days. If the repeat test confirms a baseline CK >5xULN, treatment should not be started. Before treatment Caution should be exercised in patients with pre-disposing factors for myopathy/ rhabdomyolysis. Such factors include: - renal impairment, - hypothyroidism, - personal or family history of hereditary muscular disorders, - previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate, - alcohol abuse, - age >70 years, - situations where an increase in plasma levels may occur, - concomitant use of fibrates. In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (>5xULN) treatment should not be started. While on treatment Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (>5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are ≤5x ULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring of the patient. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment. In clinical trials there was no evidence of increased skeletal muscle effects in the small number of patients dosed with rosuvastatin and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, cyclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of rosuvastatin and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose of rosuvastatin is contraindicated with concomitant use of a fibrate (see sections 4.5 and 4.8). Rosuvastatin / Ezetimibe (Zenon) should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures). Liver effects In controlled co-administration trials in patients receiving ezetimibe with statin, consecutive transaminase elevations (≥3 × the upper limit of normal [ULN]) have been observed. It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose. In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with rosuvastatin. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, Rosuvastatin / Ezetimibe (Zenon) is not recommended (see section 5.2). Liver disease and alcohol As with other HMG-CoA reductase inhibitors, rosuvastatin should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease. Renal effects Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of rosuvastatin, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg. Diabetes mellitus Some evidence suggests that statins as a class raise blood glucose and, in some patients at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI > 30 kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines. In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/L. Interstitial lung disease Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued. Severe cutaneous adverse reactions Severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with rosuvastatin. At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of this reaction appears Rosuvastatin / Ezetimibe (Zenon) must be discontinued immediately and an alternative treatment should be considered. If the patient has developed a serious reaction such as SJS or DRESS with the use of Rosuvastatin / Ezetimibe (Zenon), treatment with Rosuvastatin / Ezetimibe (Zenon) must not be restarted in this patient at any time. Protease inhibitors Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of Rosuvastatin / Ezetimibe (Zenon) in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating rosuvastatin doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of rosuvastatin is adjusted. Fibrates The safety and efficacy of ezetimibe administered with fibrates have not been established. If cholelithiasis is suspected in a patient receiving Rosuvastatin / Ezetimibe (Zenon) and fenofibrate, gallbladder investigations are indicated and this therapy should be discontinued. Anticoagulants If Rosuvastatin / Ezetimibe (Zenon) is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored. Fusidic acid Rosuvastatin / Ezetimibe (Zenon) must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g., for the treatment of severe infections, the need for co-administration of Rosuvastatin / Ezetimibe (Zenon) and fusidic acid should only be considered on a case by case basis and under close medical supervision. Race Pharmacokinetic studies show an increase in exposure of rosuvastatin in Asian subjects compared with Caucasians. Pediatric population Rosuvastatin / Ezetimibe (Zenon) is not recommended for use in children and adolescents of less than 18 years of age, due to insufficient data on safety and efficacy. Rosuvastatin / Ezetimibe (Zenon) contains lactose monohydrate and sodium Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'. |
| Drug Interaction | Contraindicated combinations: Ciclosporin: Concomitant administration of Rosuvastatin / Ezetimibe (Zenon) with ciclosporin is contraindicated because of the rosuvastatin (see section 4.3). During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). Concomitant administration did not affect plasma concentrations of ciclosporin. In a study of eight post-renal transplant patients with creatinine clearance of >50 mL/min on a stable dose of ciclosporin, a single 10-mg dose of ezetimibe resulted in a 3.4-fold (range 2.3 to 7.9-fold) increase in the mean AUC for total ezetimibe compared to a healthy control population, receiving ezetimibe alone, from another study (n=17). In a different study, a renal transplant patient with severe renal impairment who was receiving ciclosporin and multiple other medications, demonstrated a 12-fold greater exposure to total ezetimibe compared to concurrent controls receiving ezetimibe alone. In a two-period crossover study in twelve healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100 mg dose of ciclosporin on Day 7 resulted in a mean 15 % increase in ciclosporin AUC (range 10 % decrease to 51 % increase) compared to a single 100 mg dose of ciclosporin alone. A controlled study on the effect of co-administered ezetimibe on ciclosporin exposure in renal transplant patients has not been conducted. Not-recommended combinations: Fibrates and other lipid-lowering products: In patients receiving fenofibrate and ezetimibe, physicians should be aware of the possible risk of cholelithiasis and gallbladder disease (see sections 4.4 and 4.8). If cholelithiasis is suspected in a patient receiving ezetimibe and fenofibrate, gallbladder investigations are indicated and this therapy should be discontinued (see section 4.8). Concomitant fenofibrate or gemfibrozil administration modestly increased total ezetimibe concentrations (approximately 1.5- and 1.7-fold respectively). Co-administration of ezetimibe with other fibrates has not been studied. Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In animal studies, ezetimibe sometimes increased cholesterol in the gallbladder bile, but not in all species . A lithogenic risk associated with the therapeutic use of ezetimibe cannot be ruled out. Concomitant use of rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin Cmax and AUC. Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (> or equal to 1g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The Rosuvastatin / Ezetimibe (Zenon) 40 mg/10 mg dose (not available in the Philippines) is contraindicated with concomitant use of a fibrate. Protease inhibitors: Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). In a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir/100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and Cmax respectively. The concomitant use of rosuvastatin and some protease inhibitor combinations may be considered after careful consideration of rosuvastatin dose adjustments based on the expected increase in rosuvastatin exposure (see sections 4.2, 4.4 and 4.5 Table 1). Transporter protein inhibitors: Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of rosuvastatin with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see sections 4.2, 4.4 and 4.5 Table 1). Fusidic acid: The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination. If treatment with systemic fusidic acid is necessary, rosuvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. Also see section 4.4. Other interactions: Cytochrome P450 enzymes: Results from in vitro and in vivo studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4). In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 drug metabolising enzymes. No clinically significant pharmacokinetic interactions have been observed between ezetimibe and drugs known to be metabolised by cytochromes P450 1A2, 2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase. Antacids: Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant. The simultaneous dosing of rosuvastatin with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied. Colestyramine: Concomitant colestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe (ezetimibe + ezetimibe glucuronide) approximately 55%. The incremental low density lipoprotein cholesterol (LDL C) reduction due to adding ezetimibe to colestyramine may be lessened by this interaction (see section 4.2). Anticoagulants, Vitamin K antagonists: Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. However, there have been post-marketing reports of increased International Normalised Ratio (INR) in patients who had ezetimibe added to warfarin or fluindione. If Rosuvastatin / Ezetimibe (Zenon) is added to warfarin, another coumarin anticoagulant, or fluindione, INR should be appropriately monitored. As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of rosuvastatin in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of rosuvastatin may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable. Clopidogrel: Clopidogrel has been shown to increase rosuvastatin exposure in patients by 2-fold (AUC) and 1.3-fold (Cmax) after administration of 300 mg clopidogrel dose, and by 1.4-fold (AUC) without effect on Cmax after repeated administration of 75 mg clopidogrel dose. Ticagrelor: Ticagrelor might affect renal excretion of rosuvastatin, increasing the risk for rosuvastatin accumulation. Although the exact mechanism is not known, in some cases, concomitant use of ticagrelor and rosuvastatin led to renal function decrease, increased CPK level and rhabdomyolysis. Erythromycin: Concomitant use of rosuvastatin and erythromycin resulted in a 20% decrease in AUC(0-t) and a 30% decrease in Cmax of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin. Oral contraceptive/hormone replacement therapy (HRT): Concomitant use of rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in women taking concomitant rosuvastatin and HRT and therefore a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated. In clinical interaction studies, ezetimibe had no effect on the pharmacokinetics of oral contraceptives (ethinyl estradiol and levonorgestrel). Other medicinal products: Based on data from specific interaction studies with rosuvastatin no clinically relevant interaction with digoxin is expected. In clinical interaction studies, ezetimibe had no effect on the pharmacokinetics of dapsone, dextromethorphan, digoxin, glipizide, tolbutamide, or midazolam, during co-administration. Cimetidine, co-administered with ezetimibe, had no effect on the bioavailability of ezetimibe. Ezetimibe/rosuvastatin: Concomitant use of 10 mg rosuvastatin and 10 mg ezetimibe resulted in a 1.2-fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between rosuvastatin and ezetimibe cannot be ruled out. |
1. We will deliver orders in the following areas (except in island barangays).
| a) Pangasinan ✔ Dagupan City |
|
| b) La Union ✔ Agoo |
|
| c) Ilocos Sur ✔ Tagudin |
|
| d) Ilocos Norte ✔ Laoag City |
|
| e) Bataan ✔ Orion |
|
| f) Abra ✔ Bangued |
|
| g) Pampanga ✔ Angeles City |
2. There are two (2) ways to receive your order:
a) via Home Delivery
b) via Store Pickup in any of the following St. Joseph Drug (pick-up point)i> branches:
✔ Perez Blvd., Dagupan City
✔ Mabini St., Poblacion West, Calasiao, Pangasinan
✔ Rizal St. corner Biagtan St., Poblacion, Mangaldan, Pangasinan
✔ Rizal St., Poblacion, San Fabian, Pangasinan
✔ Charms Bldg., Poblacion, Pozzorubio, Pangasinan
✔ CB Mall, Mc Arthur Highway, Nancayasan, Urdaneta, Pangasinan
✔ Zone 1 Market Road corner McArthur Highway, Villasis, Pangasinan
✔ Roxas corner Malong St., San Carlos, Pangasinan
✔ Calvo St., Mangatarem, Pangasinan
✔ Poblacion, Basista, Pangasinan
✔ Poblacion, Binmaley, Pangasinan
✔ Solis St., Brgy. Poblacion, Lingayen, Pangasinan
✔ Poblacion, Quezon Avenue, Alaminos, Pangasinan
✔ Concordia (Pob.), Bolinao, Pangasinan
✔ National Road, Poblacion, Bani, Pangasinan
✔ Mother Goose Bldg., Tapuac District, Dagupan City, Pangasinan
✔ Joleco Bldg., I, A.B. Fernandez Ave., Dagupan City, Pangasinan
✔ E&J Bldg., Milo Street, Manaoag, Pangasinan
✔ Panda Ave., Poblacion, Mapandan, Pangasinan
✔ San Guillermo, San Jacinto, Pangasinan
✔ Blue Horizon Bldg., Quezon Blvd., Poblacion, Alaminos City, Pangasinan
✔ CentroMart, Rizal St., Lingayen, Pangasinan
✔ Poblacion, Aguilar, Pangasinan
✔ Romulo Highway, Poblacion, Bugallon ,Pangasinan
✔ Gen. Luna St., Poblacion, Rosales, Pangasinan
✔ Quezon Blvd., Tayug, Pangasinan
✔ National Road, Umingan, Pangasinan
✔ Poblacion East, Alcala, Pangasinan
✔ M.H. Del Pilar St., Bayambang, Pangasinan
✔ CSI, Malasiqui, Pangasinan
✔ P. Tavera St., Poblacion, Binalonan, Pangasinan
✔ Guiset Sur, San Manuel, Pangasinan
✔ Poblacion West, Asingan, Pangasinan
✔ G/F Magic Mall, Alexander St., Urdaneta City, Pangasinan
✔ Poblacion, Infanta, Pangasinan
✔ Agbayani St., Poblacion, Sual, Pangasinan
✔ Poblacion, Urbiztondo, Pangasinan
✔ Poblacion, Sta.Barbara, Pangasinan
✔ Victoria Rd., San Nicolas Norte, Agoo, La Union
✔ CSI City Mall, Biday, San Fernando City, La Union
✔ Osmeña Street, San Fernando City, La Union
✔ Poblacion East, Rosario, La Union
✔ Brgy. Lacong, Tagudin, Ilocos Sur
✔ Hennady Bldg. McArthur Poblacion, Brgy. V, Bantay, Ilocos Sur
✔ National Highway, San Antonio, Candon City, Ilocos Sur
✔ Quezon Avenue, Vigan City, Ilocos Sur
✔ City Galore Square, J.P. Rizal cor. Ligo St., Laoag City, Ilocos Norte
✔ Trece Grande Bldg., 187 JP Rizal St. Cor. Dr. Damaso Samonte St. Brgy 19, Laoag City, Ilocos Norte
✔ National Road, San Vicente, Orion, Bataan
✔ Taft St., Zone 5, Bangued, Abra
✔ Washington St., Brgy 2 Abian, Batac, Ilocos Norte
✔ Middle Session, Baguio City, Benguet
✔ G/F Senvik Loy Bldg., La Trinindad, Benguet
✔ CSI Warehouse, Purok I Palanginan, Iba, Zambales
✔ Magic Mall, Poblacion, Sta. Cruz, Zambales
✔ Sto. Rosario St., Sto. Domingo, Angeles City, Pampanga
3. We charge the following delivery fee:
| Mode of Delivery | Delivery Fee |
|---|---|
| Home Delivery | Delivery fee starts at P60.00 for the first four (4) kilometers. Additional amount will be charged depending on the distance of the shipping address you specified (please refer to the Shipping Fee Directory). |
| Store Pickup | Free of Charge |
4. We will deliver your order as follows:
a) for Home Delivery
| Orders Received | Delivery Schedule |
|---|---|
| Before 1:00pm | Same day delivery within 2:00pm to 6:00pm |
| After 1:00pm | Next day delivery within 2:00pm to 6:00pm |
b) for Store Pick-up
You may expect your order to be ready within 2 hours to a day (depending on the availability of ordered item) upon placement of order. You will be notified via call/SMS once your order is ready for pick-up. We encourage you to claim your order within 3 days (during store hours) upon receipt of advice that your order is ready for pick-up, otherwise, such shall deemed as cancelled.
5. We will deliver your order from Monday to Sunday (including holidays) from 2:00pm to 6:00pm.
6. There are two (2) ways to track your order:
a) For every change in the order status, an email will be sent to you.
b) You can also check your order status by signing-in to your account. Just go to “My Account” and click “Orders” to display the order status.
7. In case you are not home when your order arrives, you may have a representative receive and pay the package for you. However, if payment was made via bank transfer, your representative shall be required to present the following:
a) Authorization Letter; and
b) Your Valid ID (with picture and signature) and that of your representative.
8. If nobody is available to receive your order, our Rider will bring your package back to St. Joseph Drug pick-up point branch nearest/ covering the shipping address you specified, for pick-up within the 3-day claiming period or you can have it redelivered but with a corresponding redelivery fee.
ITEM RETURN/ EXCHANGE/ REFUND1. All products ordered from St. Joseph Drug are subject to quality checking by our designated personnel prior to delivery to/ pick-up by customers.
a) Upon delivery to / pick-up by customer:
✔ Please inspect your package in the presence of our Rider/Pharmacy Assistant. Your signature on the Acknowledgement Receipt signifies that you have received the products completely, correctly, and in good condition (not damaged / defective and / or expiring / expired).
✔ You may refuse to accept the product if such is incorrect, incomplete, or not in good condition. For home delivery, we will redeliver the replacement or additional item/quantity free of delivery charge.
b) After delivery to / pick-up by customer:
✔ We will still accommodate request for item return / exchange / refund under the following conditions:
- Promptly returned within 7 days upon receipt of the product
- Duly supported by St. Joseph Drug official receipt
Note : We may require additional documents (e.g. photo of the affected product) to support your request.
✔ The following items will be acceptable:
- items in good condition provided such are:
- not in a vial
- not loose tablets/capsules
Note : The product must be in its original box/packaging (unused) and complete with gift/promo item (if any).
- products with explicit manufacturing defect
Note : Damaged / defective items due to customer's mishandling or improper use will not be accepted.
✔ Once your request is approved, we will redeliver the replacement or additional item/quantity but with a corresponding redelivery fee (except for products with explicit manufacturing defect which we will redeliver free of delivery charge).
✔ Requests for refund will be reviewed and handled on a case-by-case basis and subject to management's approval.
2. To request for item return/ exchange/ refund, perform any of the following:
a) contact 0917-565-3700 or 0998-530-3700; or
b) report via our live chat/ messaging; or
c) proceed to St. Joseph Drug Perez Blvd., Dagupan City branch.
Note : Request for return/ exchange/ refund of items ordered via our Online Store will not be accepted in any other St. Joseph Drug branches.
3. Requests for item return/ exchange/ refund will be processed within 2-3 working days upon receipt of the required supporting documents. You shall be notified via call/ SMS once the request has been approved.
Neque porro quisquam est qui dolorem ipsum quia dolor sit amet
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla at venenatis eros. Nulla efficitur, orci ut cursus consectetur, nisi elit convallis odio, non hendrerit arcu tortor aliquet eros. Nullam imperdiet diam ut neque ullamcorper semper. Mauris consequat ex sed elit venenatis, eu varius nulla posuere. Nullam gravida mattis velit, id commodo nunc rhoncus ut. Phasellus congue felis tortor, nec eleifend lacus tincidunt vitae. Nullam dapibus tempus tempor. Maecenas massa neque, tempus in efficitur at, scelerisque sed tortor. Morbi vulputate ipsum odio, non posuere sem suscipit accumsan. Cras fermentum nunc quis tempor iaculis. Praesent dictum augue sit amet neque faucibus, ac varius enim convallis. Curabitur volutpat ligula sit amet nibh vehicula egestas. Etiam eget dolor ipsum. Phasellus varius, metus sit amet aliquet tempor, erat ante rhoncus magna, quis vehicula tortor nunc at ipsum. Duis vitae erat vitae turpis cursus pretium. Quisque pulvinar sapien at mi efficitur, sed faucibus nulla accumsan.
Ut a leo interdum, imperdiet ante quis, euismod quam. Nam eget auctor risus. In a bibendum diam. Curabitur non lectus pharetra, maximus dolor mattis, auctor dolor. Maecenas placerat ipsum vitae elementum vulputate. Morbi lacinia libero lorem, in dignissim ante convallis at. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Sed in purus vulputate sem tempor tincidunt ac sed turpis. Pellentesque erat justo, feugiat eget vestibulum molestie, cursus ac ex. Phasellus magna enim, placerat non lacus varius, cursus consectetur urna
Phasellus finibus nulla vitae malesuada efficitur. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus sed pharetra risus. Quisque ante sem, faucibus id velit eget, bibendum sodales purus. Donec congue ipsum leo, aliquet aliquam lectus suscipit et. Pellentesque viverra, enim et pulvinar aliquet, dolor magna gravida lectus, sit amet pellentesque turpis elit id enim. Nulla a lectus viverra, ultricies urna ac, cursus turpis. Sed et purus vitae nunc molestie molestie sit amet eget nisl. Ut non nunc erat. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus
Suspendisse imperdiet enim in porttitor dignissim. Nam iaculis enim vel nunc commodo cursus. Donec vitae magna eget nunc fringilla pharetra vitae id risus. Proin in aliquam ex. Ut purus sem, fermentum ut aliquam at, ornare quis nisl. Aliquam feugiat dapibus nunc, sit amet aliquam metus sollicitudin eget. Integer gravida ligula vitae leo suscipit, eget pretium augue tempus. Integer fringilla justo id purus pulvinar iaculis. Fusce in lorem pulvinar, suscipit ipsum id, volutpat dui. Fusce eu sem sapien. Duis sit amet nisi leo.
